Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Reference: Temozolomide for Anaplastic Glioma
The CATNON trial demonstrated a survival benefit with adjuvant temozolomide in patients with IDH-mutated astrocytoma compared to radiotherapy alone. Concurrent temozolomide did not
New Protocol: Sacituzumab Govitecan + Pembrolizumab for Triple-Negative Metastatic Breast Cancer
ASCENT-04 phase 3 trial showed that sacituzumab govitecan plus pembrolizumab significantly improved progression-free survival compared to chemotherapy plus pembrolizumab in patient
New Protocol: Lenvatinib with Bevacizumab for Gynecological Clear Cell Carcinoma
In this phase 2 trial of pembrolizumab plus lenvatinib in patients with recurrent gynaecological clear cell carcinoma, the combination of lenvatinib and pembrolizumab showed a 40%
New Protocol: Letrozole and Palbociclib with Trastuzumab and Pertuzumab for Neoadjuvant Triple-Positive Breast Cancer
The TOUCH trial showed that palbociclib and letrozole combined with dual anti-HER2 therapy achieved similar pCR rates to paclitaxel in HR-positive/HER2-positive early breast cancer
New Reference: Palbociclib Addition to Maintenance Therapy in Triple-Positive Breast Cancer
The addition of palbociclib to maintenance anti-HER2 and endocrine therapies significantly improved progression-free survival in patients with hormone-receptor-positive, HER2-posit
New Reference: Olaparib for PALB2 or BRCA1/2 Mutated Breast Cancer
The phase II TBCRC 048 study found olaparib to be effective in metastatic breast cancer patients with germline PALB2 or somatic BRCA1/2 mutations. The overall response rate was sig
New Protocol: Ultra-Low Dose Nivolumab for Advanced Solid Tumors
Ultra-low-dose nivolumab significantly improved overall survival compared to chemotherapy in patients with relapsed refractory solid tumors while reducing severe toxicities. The re
New Reference: Nivolumab for Advanced Gastric/Esophageal AdenoCa
Nivolumab combined with chemotherapy continues to show superior overall survival and progression-free survival compared to chemotherapy alone at 5 years in advanced gastroesophagea
New Reference: Camrelizumab with Chemotherapy for Advanced Nasopharyngeal Carcinoma
The addition of camrelizumab to chemotherapy provided significant improvement in overall survival in patients with recurrent or metastatic nasopharyngeal carcinoma. The trial demon
